Not exact matches
Instead,
ezetimibe blocks dietary cholesterol absorption
in the gut by inhibiting the NPC1L1 protein, perhaps approximating the effect of having only one working copy of the NPC1L1 gene.
ORLANDO, Fla. — Adding a pharmaceutical form of the B vitamin niacin — but not the drug
ezetimibe — to a cholesterol - lowering statin drug appears to reduce artery plaque buildup
in patients with coronary artery disease, according to much - anticipated results announced at a press conference November 15.
The trial was designed to compare outcomes — such as cardiovascular - related death and heart attack —
in patients taking a statin plus
ezetimibe versus patients taking a statin plus placebo.
Among medications that lower cholesterol,
ezetimibe is not
in the widely prescribed class of drugs called statins, which stop the body from manufacturing its own cholesterol.
Hearings
in January revealed that the release of negative results of a clinical trial of
ezetimibe had been delayed.
This was the issue
in last winter's congressional investigation into the nonstatin cholesterol - lowering drug
ezetimibe, sold as Zetia and contained
in Vytorin.
(
Ezetimibe on its own is sold under the name Zetia, which was first approved
in 2002.)
Ezetimibe works
in a different way from statins.
Statins block cholesterol made
in the liver, while
ezetimibe blocks the absorption of cholesterol
in the gut.